你好,请登录   免费注册    |    收藏本站
联系电话: 0574-87917803
联系电话: call_new 0574-87917803
HEY-T30
HEY-T30
规格:
货期:
编号:TS179035
品牌:Testobio
产品名称: HEY-T30
商品货号: TS179035
Organism: Homo sapiens, human
Tissue: ovary
Cell Type: ovarian carcinoma
Product Format: frozen
Morphology: epithelial-like
Culture Properties: adherent
Biosafety Level: 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease: papillary cystadenocarcinoma of the ovary
Gender: female
Applications: This cell line can be used to study resistance to microtubule stabilizing agents and other chemotherapy resistance mechanisms.
Storage Conditions: liquid nitrogen vapor phase
Images: Cell Micrograph of TS179035
Derivation: The parental cell line, HEY, was derived from a human ovarian cancer xenograft originally grown from a peritoneal sample from a patient with moderately differentiated papillary cystadenocarcinoma of the ovary. CRL-3252, HEY-T30, is a derivative of the HEY cell line and is resistant to Taxol. xa0It was developed by exposure of its parental cell line, HEY, to stepwise escalating concentrations of Taxol over a 6-month period and it is maintained in medium containing 30 nmol/L Taxol.
Receptor Expression:

Insulin-like growth factor 2 (IGF2; documented in PubMed 20404007)

Complete Growth Medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium:
  • 30 nM Paclitaxel
  • fetal bovine serum to a final concentration of 10%

Subculturing: Note: Add Taxol to FBS-containing RPMI-1640 medium each time cells are fluid changed or manipulated.xa0

Volumes used in this subculture protocol are for a 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.

  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 1.0 to 2.0 mL Ca++/Mg++ free Dulbeccos phosphate-buffered saline (D-PBS) (ATCC® No. 30-2020) or 0.25% (w/v) Trypsin - 0.53 mM EDTA (ATCC®xa0No. 30-2101) solution to remove all traces of serum which contains trypsin inhibitor.
  3. Add 1.0 to 2.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).xa0
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Transfer cell suspension to a centrifuge tube and spin at approximately 125 x g for 5 to 10 minutes. Discard supernatant.
  6. Resuspend the cell pellet in 10mL fresh growth medium.xa0
  7. Add appropriate aliquots of the cell suspension to new culture vessels.
  8. Incubate cultures at 37°C.

Subcultivation ratio: A subcultivation ratio of 1:3 to 1:12 is recommended.
Medium renewal: 2 to 3 times weekly
Culture Conditions: Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
STR Profile: Amelogenin: X
CSF1PO: 10,11
D13S317: 11
D16S539: 8,12
D5S818: 11,12
D7S820: 12
THO1: 8,9.3
TPOX: 11
vWA: 16,17
Population Doubling Time: 18-22 hours (in e-mail from Dr. Brouwer dated 12/02/14)
Name of Depositor: Jurriaan Brouwer-Visser Institution: Albert Einstein College of Medicine, Bronx, NY
Year of Origin: 2006
References:

Buick RN, et al. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res. 45: 3668-3676, 1985. PubMed: 4016745

Huang GS, et al. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin. Cancer Res. 16(11): 2999–3010, 2010. PubMed: 20404007

King ER, et al. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol. Oncol. 123(1): 13-18, 2011. PubMed: 21726895

首页 > 产品中心 > 微生物培养 > 菌株 > null > HEY-T30

HEY-T30

  • 货号: TS179035
  • 好评
询价
  • 品牌 : TESTOBIO
产品名称: HEY-T30
商品货号: TS179035
Organism: Homo sapiens, human
Tissue: ovary
Cell Type: ovarian carcinoma
Product Format: frozen
Morphology: epithelial-like
Culture Properties: adherent
Biosafety Level: 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease: papillary cystadenocarcinoma of the ovary
Gender: female
Applications: This cell line can be used to study resistance to microtubule stabilizing agents and other chemotherapy resistance mechanisms.
Storage Conditions: liquid nitrogen vapor phase
Images: Cell Micrograph of TS179035
Derivation: The parental cell line, HEY, was derived from a human ovarian cancer xenograft originally grown from a peritoneal sample from a patient with moderately differentiated papillary cystadenocarcinoma of the ovary. CRL-3252, HEY-T30, is a derivative of the HEY cell line and is resistant to Taxol. xa0It was developed by exposure of its parental cell line, HEY, to stepwise escalating concentrations of Taxol over a 6-month period and it is maintained in medium containing 30 nmol/L Taxol.
Receptor Expression:

Insulin-like growth factor 2 (IGF2; documented in PubMed 20404007)

Complete Growth Medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium:
  • 30 nM Paclitaxel
  • fetal bovine serum to a final concentration of 10%

Subculturing: Note: Add Taxol to FBS-containing RPMI-1640 medium each time cells are fluid changed or manipulated.xa0

Volumes used in this subculture protocol are for a 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.

  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 1.0 to 2.0 mL Ca++/Mg++ free Dulbeccos phosphate-buffered saline (D-PBS) (ATCC® No. 30-2020) or 0.25% (w/v) Trypsin - 0.53 mM EDTA (ATCC®xa0No. 30-2101) solution to remove all traces of serum which contains trypsin inhibitor.
  3. Add 1.0 to 2.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).xa0
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Transfer cell suspension to a centrifuge tube and spin at approximately 125 x g for 5 to 10 minutes. Discard supernatant.
  6. Resuspend the cell pellet in 10mL fresh growth medium.xa0
  7. Add appropriate aliquots of the cell suspension to new culture vessels.
  8. Incubate cultures at 37°C.

Subcultivation ratio: A subcultivation ratio of 1:3 to 1:12 is recommended.
Medium renewal: 2 to 3 times weekly
Culture Conditions: Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
STR Profile: Amelogenin: X
CSF1PO: 10,11
D13S317: 11
D16S539: 8,12
D5S818: 11,12
D7S820: 12
THO1: 8,9.3
TPOX: 11
vWA: 16,17
Population Doubling Time: 18-22 hours (in e-mail from Dr. Brouwer dated 12/02/14)
Name of Depositor: Jurriaan Brouwer-Visser Institution: Albert Einstein College of Medicine, Bronx, NY
Year of Origin: 2006
References:

Buick RN, et al. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res. 45: 3668-3676, 1985. PubMed: 4016745

Huang GS, et al. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin. Cancer Res. 16(11): 2999–3010, 2010. PubMed: 20404007

King ER, et al. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol. Oncol. 123(1): 13-18, 2011. PubMed: 21726895

合作单位: